The Molecular Basis of Ubiquitin-Conjugating Enzymes (E2s) as a Potential Target for Cancer Therapy

Area of Science:

• Biochemistry and Molecular Biology
• Cellular Biology
• Oncology

Background:

• Ubiquitin-conjugating enzymes (E2s) are key components of the ubiquitin-proteasome pathway, essential for protein degradation and cellular regulation.
• E2s dictate the type of ubiquitin chain linkage, influencing substrate protein stability and activity, thereby regulating diverse biological processes.
• Dysregulation of E2s is increasingly recognized in various cancers, highlighting their potential as therapeutic targets.

Purpose of the Study:

• To systematically review the molecular basis of E2s as therapeutic targets in human diseases, particularly cancer.
• To provide a comprehensive overview of E2s' roles in the ubiquitin-proteasome pathway, their structures, and associated biological functions.
• To summarize current strategies, including inhibitors and microRNAs, for targeting E2s.

Main Methods:

• Literature review focusing on the ubiquitin-proteasome pathway, E2 enzyme structure-function relationships, and their involvement in biological processes.
• Analysis of studies reporting E2 dysregulation in cancer.
• Compilation of information on existing and emerging E2-targeting agents and microRNAs.

Main Results:

• E2s play a critical role in determining ubiquitin chain topology, which impacts substrate fate and cellular signaling.
• Aberrant E2 activity is a common feature in many cancers, suggesting their involvement in tumorigenesis.
• A range of inhibitors and microRNAs targeting E2s have been identified, offering potential therapeutic avenues.

Conclusions:

• E2 enzymes represent a promising class of therapeutic targets due to their central role in protein homeostasis and disease pathogenesis.
• Understanding the molecular intricacies of E2s is crucial for developing effective anti-cancer drugs.
• This review provides a foundation for future research and drug development targeting E2 enzymes.